Skip to main content

Advertisement

Table 1 Study schedule

From: Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A

Time point Screening
< 2 weeks
Baseline
Day 0
Visit 3
Month 11
Visit 4
Month 32
Visit 5
Month 6
Visit 6
Month 9
Visit 7
Month 122
Informed consent X       
Record demographics & handedness X       
Review inclusion/exclusion criteria X X      
Review medical history X X      
Details of stroke X       
Pre stroke function (inc Oxford Handicap Scale)) X       
Abbreviated Mental Test Score (AMTS) X       
Sheffield Aphasia Screening Test X       
Action Research Arm Test (ARAT) X X X X    X
Motricity Index   X X X    X
Grip strength   X X X    X
Nine Hole Peg Test   X X X    X
Modified Ashworth Scale X X X X    X
Self rating of severity   X X X    X
Upper limb pain (numerical rating scale)3   X X X    X
Patient selects upper limb goals   X      
Review upper limb goal attainment    X     
Barthel ADL Index3 X   X3 X3    X3
Quality of life – Stroke Impact Scale3 X   X3 X3    X3
Quality of life – Euroquol-5D3 X   X3 X3    X3
Resource utilisation questions3 X   X3 X3    X3
Pregnancy test4   X   X6 X6 X6  
Randomisation   X      
Treatment with Dysport5   X   X7 X7 X7  
Commencement of 4 week upper limb therapy programme   X   X7 X7 X7  
Clinical assessment by study therapist   X   X X X X
Concomitant medications (inc anti-spasticity treatment) X X X X    X
Adverse Events   X X X    X
Participants views and experience    X     X
  1. 1. Visit window is +3 days.
  2. 2. Visit window is +5 days.
  3. 3. Questionnaires will be sent to the participant for completion 1 week prior to the visit. Participants will bring completed forms to the visit.
  4. 4. For female participants at risk of pregnancy.
  5. 5. Participants in the intervention group only.
  6. 6. Pregnancy test to be performed prior to any additional botulinum toxin injections.
  7. 7. Additional botulinum toxin injections/upper limb therapy to be provided if clinically appropriate